| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 55 | 2021 | 763 | 4.410 |
Why?
|
| Epilepsy | 14 | 2023 | 397 | 3.910 |
Why?
|
| Deep Brain Stimulation | 10 | 2018 | 54 | 3.530 |
Why?
|
| Laser Therapy | 5 | 2023 | 142 | 3.340 |
Why?
|
| Neurosurgical Procedures | 11 | 2021 | 213 | 3.080 |
Why?
|
| Parkinson Disease | 10 | 2018 | 132 | 3.030 |
Why?
|
| Epilepsy, Temporal Lobe | 13 | 2023 | 122 | 2.980 |
Why?
|
| Subthalamic Nucleus | 8 | 2018 | 22 | 2.630 |
Why?
|
| Glioma | 28 | 2021 | 285 | 2.430 |
Why?
|
| Neuronavigation | 5 | 2020 | 21 | 2.420 |
Why?
|
| Stereotaxic Techniques | 9 | 2020 | 69 | 2.190 |
Why?
|
| Oligodendroglioma | 12 | 2011 | 45 | 2.050 |
Why?
|
| Drug Resistant Epilepsy | 4 | 2023 | 42 | 1.830 |
Why?
|
| Radiosurgery | 16 | 2020 | 272 | 1.680 |
Why?
|
| Neurosurgery | 5 | 2020 | 84 | 1.660 |
Why?
|
| Electroencephalography | 17 | 2023 | 709 | 1.490 |
Why?
|
| Lennox Gastaut Syndrome | 2 | 2020 | 14 | 1.450 |
Why?
|
| Magnetic Resonance Imaging | 26 | 2023 | 3362 | 1.440 |
Why?
|
| Corpus Callosum | 2 | 2020 | 56 | 1.420 |
Why?
|
| Pituitary Neoplasms | 3 | 2017 | 62 | 1.310 |
Why?
|
| Humans | 123 | 2023 | 86643 | 0.980 |
Why?
|
| Male | 68 | 2023 | 40965 | 0.940 |
Why?
|
| Seizures | 9 | 2023 | 297 | 0.910 |
Why?
|
| Antiparkinson Agents | 2 | 2013 | 15 | 0.910 |
Why?
|
| Astrocytoma | 11 | 2010 | 82 | 0.850 |
Why?
|
| Internal Capsule | 1 | 2021 | 4 | 0.840 |
Why?
|
| Female | 69 | 2021 | 44532 | 0.820 |
Why?
|
| Treatment Outcome | 28 | 2023 | 7993 | 0.820 |
Why?
|
| Middle Aged | 48 | 2021 | 25028 | 0.810 |
Why?
|
| Cross Infection | 2 | 2019 | 141 | 0.770 |
Why?
|
| Neuroendoscopy | 1 | 2020 | 14 | 0.740 |
Why?
|
| Ventriculostomy | 1 | 2020 | 26 | 0.740 |
Why?
|
| Adult | 48 | 2021 | 25648 | 0.730 |
Why?
|
| Moraxellaceae Infections | 1 | 2019 | 2 | 0.700 |
Why?
|
| Basal Ganglia | 1 | 2019 | 42 | 0.700 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2021 | 157 | 0.700 |
Why?
|
| Molecular Typing | 1 | 2019 | 17 | 0.700 |
Why?
|
| Brain | 17 | 2022 | 2216 | 0.690 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 53 | 0.680 |
Why?
|
| Terminology as Topic | 1 | 2020 | 217 | 0.680 |
Why?
|
| Gait | 3 | 2015 | 80 | 0.660 |
Why?
|
| Hippocampus | 7 | 2022 | 442 | 0.660 |
Why?
|
| Blood-Brain Barrier | 7 | 2014 | 70 | 0.660 |
Why?
|
| Capillaries | 3 | 2006 | 91 | 0.660 |
Why?
|
| Disease Outbreaks | 1 | 2019 | 154 | 0.650 |
Why?
|
| Stem Cell Transplantation | 1 | 2019 | 183 | 0.630 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2015 | 1313 | 0.630 |
Why?
|
| Sclerosis | 1 | 2017 | 28 | 0.630 |
Why?
|
| Electrodes, Implanted | 2 | 2016 | 171 | 0.620 |
Why?
|
| Cerebral Hemorrhage | 4 | 2023 | 325 | 0.610 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2019 | 237 | 0.610 |
Why?
|
| Craniopharyngioma | 1 | 2017 | 11 | 0.610 |
Why?
|
| Levodopa | 2 | 2015 | 36 | 0.600 |
Why?
|
| Anesthesia, General | 2 | 2018 | 114 | 0.600 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2020 | 223 | 0.590 |
Why?
|
| Gait Disorders, Neurologic | 2 | 2018 | 16 | 0.590 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2019 | 579 | 0.580 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2016 | 9 | 0.560 |
Why?
|
| Hydrocephalus | 2 | 2020 | 101 | 0.550 |
Why?
|
| Meningeal Neoplasms | 3 | 2011 | 61 | 0.550 |
Why?
|
| Glioblastoma | 8 | 2003 | 255 | 0.550 |
Why?
|
| Muscle Denervation | 1 | 2015 | 3 | 0.540 |
Why?
|
| Torticollis | 1 | 2015 | 11 | 0.540 |
Why?
|
| Meningioma | 2 | 2011 | 60 | 0.540 |
Why?
|
| Aged | 35 | 2021 | 18415 | 0.540 |
Why?
|
| Peripheral Nerves | 1 | 2015 | 36 | 0.530 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2015 | 19 | 0.530 |
Why?
|
| Craniotomy | 4 | 2017 | 88 | 0.530 |
Why?
|
| Chromosomes, Human, Pair 19 | 9 | 2011 | 59 | 0.530 |
Why?
|
| Young Adult | 16 | 2021 | 5976 | 0.530 |
Why?
|
| Epilepsies, Partial | 2 | 2013 | 42 | 0.520 |
Why?
|
| Chromosomes, Human, Pair 1 | 8 | 2011 | 100 | 0.520 |
Why?
|
| Postoperative Complications | 6 | 2019 | 2207 | 0.510 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 9 | 2023 | 92 | 0.500 |
Why?
|
| Intracranial Arteriovenous Malformations | 2 | 2014 | 104 | 0.490 |
Why?
|
| Chorea | 1 | 2014 | 13 | 0.480 |
Why?
|
| Deep Sedation | 1 | 2014 | 15 | 0.480 |
Why?
|
| Scalp | 4 | 2022 | 72 | 0.480 |
Why?
|
| Essential Tremor | 1 | 2013 | 6 | 0.480 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2007 | 1204 | 0.470 |
Why?
|
| Stroke | 1 | 2023 | 965 | 0.470 |
Why?
|
| Radio Waves | 1 | 2013 | 17 | 0.470 |
Why?
|
| Retrospective Studies | 19 | 2023 | 8489 | 0.470 |
Why?
|
| Electrocoagulation | 1 | 2013 | 22 | 0.470 |
Why?
|
| Reoperation | 1 | 2016 | 597 | 0.460 |
Why?
|
| Microsurgery | 2 | 2013 | 84 | 0.450 |
Why?
|
| Decompression, Surgical | 2 | 2020 | 87 | 0.440 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2021 | 2601 | 0.440 |
Why?
|
| Cerebellar Neoplasms | 4 | 2006 | 36 | 0.440 |
Why?
|
| Dopamine Agonists | 1 | 2012 | 27 | 0.430 |
Why?
|
| Capillary Permeability | 4 | 2006 | 130 | 0.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2006 | 2438 | 0.420 |
Why?
|
| Carmustine | 2 | 2010 | 70 | 0.420 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2020 | 81 | 0.420 |
Why?
|
| Lateral Ventricles | 1 | 2011 | 12 | 0.420 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2010 | 138 | 0.410 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2011 | 48 | 0.400 |
Why?
|
| Regional Blood Flow | 6 | 2005 | 197 | 0.380 |
Why?
|
| Spinal Cord Diseases | 2 | 2020 | 29 | 0.370 |
Why?
|
| Cerebral Cortex | 5 | 2020 | 584 | 0.370 |
Why?
|
| Sleep | 6 | 2022 | 444 | 0.370 |
Why?
|
| Brachytherapy | 6 | 2005 | 119 | 0.370 |
Why?
|
| Medulloblastoma | 2 | 2006 | 36 | 0.360 |
Why?
|
| Survival Rate | 17 | 2013 | 1863 | 0.360 |
Why?
|
| Genotype | 9 | 2019 | 1851 | 0.360 |
Why?
|
| Endoscopy | 1 | 2013 | 332 | 0.350 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2010 | 138 | 0.340 |
Why?
|
| Endothelial Growth Factors | 2 | 1999 | 55 | 0.330 |
Why?
|
| Prospective Studies | 9 | 2018 | 4213 | 0.310 |
Why?
|
| Cranial Irradiation | 6 | 2013 | 36 | 0.300 |
Why?
|
| Adolescent | 15 | 2020 | 8981 | 0.300 |
Why?
|
| Follow-Up Studies | 14 | 2020 | 3640 | 0.300 |
Why?
|
| Prone Position | 2 | 2017 | 56 | 0.290 |
Why?
|
| Child | 10 | 2021 | 6927 | 0.280 |
Why?
|
| Cerebrovascular Circulation | 5 | 2010 | 212 | 0.280 |
Why?
|
| Electrocorticography | 3 | 2020 | 37 | 0.270 |
Why?
|
| Biopsy, Needle | 2 | 1999 | 235 | 0.270 |
Why?
|
| Evidence-Based Medicine | 2 | 2004 | 429 | 0.260 |
Why?
|
| Deglutition | 2 | 2015 | 73 | 0.250 |
Why?
|
| Hematoma, Subdural | 1 | 2004 | 23 | 0.250 |
Why?
|
| Combined Modality Therapy | 9 | 2013 | 1686 | 0.250 |
Why?
|
| Beauty | 1 | 2023 | 8 | 0.240 |
Why?
|
| Brain Abscess | 1 | 2003 | 8 | 0.240 |
Why?
|
| Wakefulness | 3 | 2020 | 134 | 0.230 |
Why?
|
| Carotid Artery, Internal | 1 | 2003 | 69 | 0.230 |
Why?
|
| Lymphoma | 1 | 2005 | 262 | 0.230 |
Why?
|
| Choline | 2 | 2005 | 23 | 0.220 |
Why?
|
| Disease Progression | 6 | 2015 | 1531 | 0.220 |
Why?
|
| Temporal Lobe | 3 | 2022 | 172 | 0.220 |
Why?
|
| Memory Consolidation | 1 | 2022 | 14 | 0.220 |
Why?
|
| Carotid Artery Diseases | 1 | 2003 | 97 | 0.220 |
Why?
|
| Tomography, Spiral Computed | 1 | 2003 | 76 | 0.220 |
Why?
|
| Intracranial Aneurysm | 1 | 2003 | 158 | 0.210 |
Why?
|
| Cerebral Angiography | 1 | 2003 | 196 | 0.210 |
Why?
|
| Prognosis | 10 | 2016 | 3679 | 0.210 |
Why?
|
| Somatosensory Cortex | 1 | 2023 | 129 | 0.210 |
Why?
|
| Gamma Rays | 1 | 2001 | 72 | 0.200 |
Why?
|
| Telomerase | 1 | 2021 | 55 | 0.200 |
Why?
|
| Motor Cortex | 1 | 2023 | 195 | 0.200 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2021 | 67 | 0.200 |
Why?
|
| Acetylcholine | 1 | 2001 | 176 | 0.200 |
Why?
|
| Gliosarcoma | 1 | 2000 | 7 | 0.200 |
Why?
|
| Prevalence | 3 | 2020 | 1239 | 0.190 |
Why?
|
| Trauma, Nervous System | 1 | 2020 | 6 | 0.190 |
Why?
|
| Blood Volume | 2 | 2006 | 51 | 0.190 |
Why?
|
| Embolization, Therapeutic | 1 | 2003 | 238 | 0.190 |
Why?
|
| Traumatology | 1 | 2020 | 27 | 0.190 |
Why?
|
| Psychosurgery | 1 | 2020 | 13 | 0.190 |
Why?
|
| Encephalitis | 2 | 2018 | 104 | 0.190 |
Why?
|
| Phenotype | 3 | 2019 | 2378 | 0.190 |
Why?
|
| Semantics | 1 | 2020 | 50 | 0.190 |
Why?
|
| Third Ventricle | 1 | 2020 | 11 | 0.190 |
Why?
|
| Spinal Diseases | 1 | 2020 | 44 | 0.190 |
Why?
|
| Theta Rhythm | 1 | 2020 | 27 | 0.190 |
Why?
|
| Surgical Oncology | 1 | 2020 | 27 | 0.190 |
Why?
|
| Skull Base | 1 | 2020 | 47 | 0.180 |
Why?
|
| Neurofibromatosis 1 | 1 | 2020 | 36 | 0.180 |
Why?
|
| Dura Mater | 1 | 2020 | 44 | 0.180 |
Why?
|
| Genetic Therapy | 3 | 2013 | 342 | 0.180 |
Why?
|
| Neurology | 1 | 2020 | 70 | 0.180 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2020 | 85 | 0.180 |
Why?
|
| Neovascularization, Pathologic | 2 | 1999 | 353 | 0.180 |
Why?
|
| Staphylococcal Infections | 2 | 2017 | 255 | 0.180 |
Why?
|
| Neurological Rehabilitation | 1 | 2019 | 1 | 0.180 |
Why?
|
| Cerebrovascular Disorders | 1 | 2020 | 143 | 0.180 |
Why?
|
| Lasers | 3 | 2023 | 106 | 0.180 |
Why?
|
| Videotape Recording | 1 | 1999 | 47 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 2 | 2000 | 1041 | 0.170 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 148 | 0.170 |
Why?
|
| Loss of Heterozygosity | 3 | 2006 | 85 | 0.170 |
Why?
|
| Lymphokines | 1 | 1999 | 76 | 0.170 |
Why?
|
| Biopsy | 7 | 2007 | 1163 | 0.170 |
Why?
|
| Thrombolytic Therapy | 1 | 2021 | 220 | 0.170 |
Why?
|
| Language | 1 | 2020 | 151 | 0.170 |
Why?
|
| Bone Transplantation | 2 | 2014 | 64 | 0.170 |
Why?
|
| Brain Waves | 1 | 2019 | 32 | 0.170 |
Why?
|
| Implantable Neurostimulators | 1 | 2018 | 12 | 0.170 |
Why?
|
| Risk Assessment | 1 | 2006 | 2261 | 0.170 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 57 | 0.160 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2019 | 137 | 0.160 |
Why?
|
| Intracranial Pressure | 2 | 2017 | 77 | 0.160 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 132 | 0.160 |
Why?
|
| Cell Survival | 1 | 2000 | 969 | 0.160 |
Why?
|
| Limbic Encephalitis | 1 | 2018 | 11 | 0.160 |
Why?
|
| Glutamate Decarboxylase | 1 | 2018 | 32 | 0.160 |
Why?
|
| Neuropsychological Tests | 2 | 2017 | 502 | 0.160 |
Why?
|
| Brain Mapping | 3 | 2020 | 548 | 0.160 |
Why?
|
| Brain Edema | 2 | 1998 | 50 | 0.160 |
Why?
|
| General Surgery | 1 | 2020 | 229 | 0.160 |
Why?
|
| Infection Control | 1 | 2019 | 115 | 0.160 |
Why?
|
| Carrier State | 1 | 2017 | 39 | 0.160 |
Why?
|
| Carrier Proteins | 1 | 2001 | 673 | 0.160 |
Why?
|
| Thymidine Kinase | 2 | 2013 | 30 | 0.150 |
Why?
|
| Blood Vessels | 1 | 1997 | 94 | 0.150 |
Why?
|
| Ganciclovir | 2 | 2013 | 49 | 0.150 |
Why?
|
| Death, Sudden | 1 | 2017 | 40 | 0.150 |
Why?
|
| Alleles | 3 | 2006 | 1128 | 0.150 |
Why?
|
| Dexamethasone | 2 | 1998 | 326 | 0.150 |
Why?
|
| Receptors, GABA-A | 1 | 1997 | 32 | 0.150 |
Why?
|
| Intracranial Hypertension | 1 | 2017 | 48 | 0.150 |
Why?
|
| Multimodal Imaging | 1 | 2017 | 110 | 0.150 |
Why?
|
| Delta Rhythm | 1 | 2016 | 19 | 0.150 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 73 | 0.150 |
Why?
|
| Databases, Factual | 2 | 2021 | 814 | 0.150 |
Why?
|
| Nerve Net | 1 | 2020 | 366 | 0.150 |
Why?
|
| Lomustine | 2 | 2006 | 26 | 0.150 |
Why?
|
| Procarbazine | 2 | 2006 | 40 | 0.150 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2016 | 9 | 0.140 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 1997 | 78 | 0.140 |
Why?
|
| Deglutition Disorders | 1 | 2018 | 115 | 0.140 |
Why?
|
| Vincristine | 2 | 2006 | 111 | 0.140 |
Why?
|
| Neurons | 2 | 2023 | 1546 | 0.140 |
Why?
|
| Pediatrics | 1 | 2020 | 344 | 0.140 |
Why?
|
| Orthopedic Procedures | 1 | 2017 | 128 | 0.140 |
Why?
|
| Epilepsy, Generalized | 1 | 2016 | 37 | 0.140 |
Why?
|
| Antibodies | 1 | 2018 | 350 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 10 | 3 | 2005 | 47 | 0.140 |
Why?
|
| Bone Matrix | 2 | 2014 | 18 | 0.140 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2017 | 86 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 1999 | 532 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 17 | 3 | 2005 | 110 | 0.130 |
Why?
|
| Neoplasm, Residual | 2 | 1995 | 162 | 0.130 |
Why?
|
| Energy Metabolism | 1 | 1997 | 271 | 0.130 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 30 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2015 | 155 | 0.120 |
Why?
|
| Mental Disorders | 1 | 2018 | 371 | 0.120 |
Why?
|
| Skull Fractures | 1 | 2014 | 24 | 0.120 |
Why?
|
| Frontal Bone | 1 | 2014 | 16 | 0.120 |
Why?
|
| Parietal Bone | 1 | 2014 | 20 | 0.120 |
Why?
|
| Gold | 1 | 2014 | 41 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1995 | 150 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 114 | 0.120 |
Why?
|
| Extracellular Space | 1 | 1994 | 90 | 0.120 |
Why?
|
| Doxorubicin | 1 | 2014 | 295 | 0.120 |
Why?
|
| Temporal Bone | 1 | 2014 | 66 | 0.120 |
Why?
|
| Risk Factors | 6 | 2020 | 5417 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2016 | 2767 | 0.110 |
Why?
|
| Dogs | 6 | 1995 | 685 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 462 | 0.110 |
Why?
|
| Hypokinesia | 1 | 2012 | 3 | 0.110 |
Why?
|
| Blood Glucose | 1 | 1997 | 873 | 0.110 |
Why?
|
| Adenoviridae | 1 | 2013 | 345 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2014 | 268 | 0.100 |
Why?
|
| Animals | 16 | 2014 | 26582 | 0.100 |
Why?
|
| Mannitol | 2 | 1989 | 49 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2011 | 292 | 0.100 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2001 | 188 | 0.100 |
Why?
|
| Syndrome | 1 | 2011 | 446 | 0.100 |
Why?
|
| Contrast Media | 3 | 2014 | 1078 | 0.090 |
Why?
|
| Thallium | 1 | 2010 | 8 | 0.090 |
Why?
|
| Radiotherapy Dosage | 5 | 2011 | 468 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2011 | 1197 | 0.090 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2010 | 20 | 0.090 |
Why?
|
| Karnofsky Performance Status | 1 | 2010 | 40 | 0.090 |
Why?
|
| Injections, Intramuscular | 1 | 2010 | 62 | 0.090 |
Why?
|
| Saline Solution, Hypertonic | 1 | 1989 | 24 | 0.090 |
Why?
|
| Iodine Radioisotopes | 3 | 2004 | 134 | 0.090 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 1989 | 32 | 0.090 |
Why?
|
| Sodium Chloride | 1 | 1989 | 88 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2013 | 510 | 0.090 |
Why?
|
| Necrosis | 3 | 2015 | 204 | 0.080 |
Why?
|
| Video Recording | 2 | 2020 | 190 | 0.080 |
Why?
|
| Cognition | 1 | 2013 | 570 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 1993 | 1056 | 0.080 |
Why?
|
| Drug Delivery Systems | 2 | 2005 | 178 | 0.080 |
Why?
|
| Allelic Imbalance | 4 | 2011 | 20 | 0.080 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 1987 | 4 | 0.080 |
Why?
|
| DNA Mutational Analysis | 2 | 2006 | 526 | 0.080 |
Why?
|
| Time Factors | 4 | 2021 | 5210 | 0.080 |
Why?
|
| Down-Regulation | 3 | 2007 | 504 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2006 | 2271 | 0.080 |
Why?
|
| Pituitary Irradiation | 1 | 2007 | 2 | 0.080 |
Why?
|
| Hypophysectomy | 1 | 2007 | 27 | 0.080 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2007 | 58 | 0.070 |
Why?
|
| Optic Nerve | 1 | 2007 | 35 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2005 | 318 | 0.070 |
Why?
|
| Ki-67 Antigen | 1 | 2007 | 64 | 0.070 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 1204 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 865 | 0.070 |
Why?
|
| Pituitary Gland | 1 | 2007 | 117 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 6509 | 0.070 |
Why?
|
| ADAM Proteins | 1 | 2006 | 11 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2007 | 163 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 3 | 2021 | 937 | 0.070 |
Why?
|
| Avian Sarcoma Viruses | 3 | 1995 | 7 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 2 | 2004 | 297 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2003 | 1464 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2007 | 294 | 0.070 |
Why?
|
| Iopamidol | 1 | 2005 | 10 | 0.070 |
Why?
|
| Adenosine | 1 | 1987 | 225 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 552 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2018 | 1823 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 1939 | 0.060 |
Why?
|
| Hypothalamic Diseases | 1 | 2004 | 2 | 0.060 |
Why?
|
| Genetic Testing | 2 | 2005 | 535 | 0.060 |
Why?
|
| Quality Control | 1 | 2004 | 117 | 0.060 |
Why?
|
| Neurocytoma | 1 | 2003 | 3 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1673 | 0.060 |
Why?
|
| Hamartoma | 1 | 2004 | 31 | 0.060 |
Why?
|
| Lipoma | 1 | 2003 | 25 | 0.060 |
Why?
|
| Research Design | 3 | 2004 | 594 | 0.060 |
Why?
|
| Neurologic Examination | 3 | 1999 | 118 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2006 | 311 | 0.060 |
Why?
|
| Genes, p53 | 1 | 2003 | 109 | 0.060 |
Why?
|
| Microsatellite Repeats | 1 | 2003 | 145 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2003 | 108 | 0.060 |
Why?
|
| Amplifiers, Electronic | 1 | 2022 | 6 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2005 | 381 | 0.060 |
Why?
|
| Amino Acids | 1 | 2003 | 252 | 0.060 |
Why?
|
| Entropy | 1 | 2002 | 38 | 0.060 |
Why?
|
| Electric Stimulation | 1 | 2023 | 347 | 0.050 |
Why?
|
| Hand | 1 | 2023 | 130 | 0.050 |
Why?
|
| Spatial Memory | 1 | 2022 | 27 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2003 | 476 | 0.050 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2003 | 92 | 0.050 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2001 | 10 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2006 | 407 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2005 | 482 | 0.050 |
Why?
|
| Hemicholinium 3 | 1 | 2001 | 1 | 0.050 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 2001 | 4 | 0.050 |
Why?
|
| Tritium | 1 | 2001 | 133 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2020 | 3612 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2006 | 1805 | 0.050 |
Why?
|
| Lateral Thalamic Nuclei | 1 | 2001 | 4 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2022 | 303 | 0.050 |
Why?
|
| Mouth Neoplasms | 1 | 2003 | 194 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 879 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 3968 | 0.050 |
Why?
|
| Organ Culture Techniques | 1 | 2001 | 135 | 0.050 |
Why?
|
| Movement | 1 | 2023 | 299 | 0.050 |
Why?
|
| ErbB Receptors | 2 | 2021 | 485 | 0.050 |
Why?
|
| Tourette Syndrome | 1 | 2001 | 25 | 0.050 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2001 | 126 | 0.050 |
Why?
|
| Mental Recall | 1 | 2022 | 159 | 0.050 |
Why?
|
| Interphase | 1 | 2000 | 34 | 0.050 |
Why?
|
| Regression Analysis | 3 | 2003 | 596 | 0.050 |
Why?
|
| Sarcoma, Experimental | 2 | 1995 | 53 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 172 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2004 | 971 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2003 | 751 | 0.050 |
Why?
|
| Biological Transport | 4 | 1991 | 396 | 0.050 |
Why?
|
| Mandible | 1 | 2001 | 119 | 0.050 |
Why?
|
| Rabbits | 1 | 2001 | 636 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2020 | 54 | 0.050 |
Why?
|
| Conservative Treatment | 1 | 2020 | 20 | 0.050 |
Why?
|
| Transplantation, Heterologous | 3 | 2001 | 363 | 0.050 |
Why?
|
| Principal Component Analysis | 2 | 2011 | 155 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2020 | 126 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2001 | 301 | 0.040 |
Why?
|
| Therapy, Computer-Assisted | 1 | 1999 | 17 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2011 | 369 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1999 | 56 | 0.040 |
Why?
|
| Pneumonia | 1 | 2020 | 179 | 0.040 |
Why?
|
| Neurophysiological Monitoring | 1 | 2018 | 11 | 0.040 |
Why?
|
| Neoplasm Transplantation | 3 | 1991 | 391 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2705 | 0.040 |
Why?
|
| Xenon | 1 | 1998 | 7 | 0.040 |
Why?
|
| Supratentorial Neoplasms | 1 | 1998 | 10 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 298 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 300 | 0.040 |
Why?
|
| Electrodes | 1 | 2018 | 78 | 0.040 |
Why?
|
| Specimen Handling | 1 | 1999 | 98 | 0.040 |
Why?
|
| Rats | 4 | 1991 | 3990 | 0.040 |
Why?
|
| Groin | 1 | 2017 | 8 | 0.040 |
Why?
|
| Polysomnography | 1 | 2018 | 151 | 0.040 |
Why?
|
| Carboxy-Lyases | 1 | 2018 | 22 | 0.040 |
Why?
|
| Barbiturates | 1 | 2017 | 12 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2003 | 629 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 466 | 0.040 |
Why?
|
| Germany | 1 | 2017 | 72 | 0.040 |
Why?
|
| Pharynx | 1 | 2017 | 45 | 0.040 |
Why?
|
| Aminoisobutyric Acids | 2 | 1987 | 4 | 0.040 |
Why?
|
| Decompressive Craniectomy | 1 | 2017 | 18 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 66 | 0.040 |
Why?
|
| Blood Flow Velocity | 2 | 1998 | 197 | 0.040 |
Why?
|
| Functional Laterality | 1 | 2018 | 201 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 94 | 0.040 |
Why?
|
| Antimetabolites | 1 | 1997 | 24 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2017 | 91 | 0.040 |
Why?
|
| Posture | 1 | 2017 | 125 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 399 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 1565 | 0.040 |
Why?
|
| Tomography, Emission-Computed | 1 | 1997 | 103 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 1999 | 927 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2018 | 267 | 0.040 |
Why?
|
| Personality | 1 | 2018 | 134 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2003 | 1076 | 0.040 |
Why?
|
| Bias | 1 | 1997 | 127 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 268 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1998 | 339 | 0.030 |
Why?
|
| Methylation | 2 | 2007 | 251 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 310 | 0.030 |
Why?
|
| Spin Labels | 1 | 2015 | 102 | 0.030 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2016 | 122 | 0.030 |
Why?
|
| Barium Sulfate | 1 | 2014 | 43 | 0.030 |
Why?
|
| Mathematics | 1 | 1995 | 190 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 1753 | 0.030 |
Why?
|
| Models, Cardiovascular | 1 | 1995 | 98 | 0.030 |
Why?
|
| Nimustine | 1 | 1994 | 1 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 241 | 0.030 |
Why?
|
| Apoptosis | 1 | 2000 | 1683 | 0.030 |
Why?
|
| Drug Implants | 2 | 2004 | 34 | 0.030 |
Why?
|
| Radiation Dosage | 2 | 1993 | 227 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 3046 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 329 | 0.030 |
Why?
|
| Interferons | 1 | 1994 | 133 | 0.030 |
Why?
|
| Radiography | 2 | 2011 | 813 | 0.030 |
Why?
|
| Anaplasia | 1 | 1993 | 5 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 1384 | 0.030 |
Why?
|
| Patient Selection | 1 | 1997 | 685 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1621 | 0.030 |
Why?
|
| Skull | 1 | 2014 | 249 | 0.030 |
Why?
|
| Kinetics | 1 | 1995 | 1513 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 1718 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 357 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 1577 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1991 | 312 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2011 | 37 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2007 | 2426 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 273 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1801 | 0.020 |
Why?
|
| Genetic Vectors | 2 | 2003 | 439 | 0.020 |
Why?
|
| Quality of Life | 2 | 1995 | 1585 | 0.020 |
Why?
|
| Osmosis | 1 | 1987 | 6 | 0.020 |
Why?
|
| Ethylnitrosourea | 1 | 1987 | 30 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 689 | 0.020 |
Why?
|
| Mice | 2 | 2014 | 11352 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 307 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2007 | 50 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 87 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1987 | 429 | 0.020 |
Why?
|
| ADAMTS Proteins | 1 | 2006 | 1 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2007 | 393 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 592 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2007 | 201 | 0.020 |
Why?
|
| Gene Expression | 1 | 2010 | 1284 | 0.020 |
Why?
|
| United States | 1 | 2018 | 6672 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2006 | 2360 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2005 | 90 | 0.020 |
Why?
|
| Exons | 1 | 2007 | 450 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 1989 | 398 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 1987 | 1047 | 0.020 |
Why?
|
| Models, Biological | 1 | 1991 | 1749 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2006 | 782 | 0.020 |
Why?
|
| Semliki forest virus | 1 | 2003 | 8 | 0.010 |
Why?
|
| Mandibular Neoplasms | 1 | 2003 | 24 | 0.010 |
Why?
|
| Lipids | 1 | 2005 | 269 | 0.010 |
Why?
|
| Capsules | 1 | 2003 | 38 | 0.010 |
Why?
|
| Liposomes | 1 | 2003 | 91 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 388 | 0.010 |
Why?
|
| Binding Sites | 1 | 2006 | 1098 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2004 | 256 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 2062 | 0.010 |
Why?
|
| Internationality | 1 | 2003 | 69 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2003 | 116 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2003 | 81 | 0.010 |
Why?
|
| Microradiography | 1 | 2001 | 2 | 0.010 |
Why?
|
| Collagen | 1 | 2003 | 269 | 0.010 |
Why?
|
| Bone Substitutes | 1 | 2001 | 9 | 0.010 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2001 | 11 | 0.010 |
Why?
|
| Swine, Miniature | 1 | 2001 | 51 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 3030 | 0.010 |
Why?
|
| Minerals | 1 | 2001 | 22 | 0.010 |
Why?
|
| Bone Plates | 1 | 2001 | 23 | 0.010 |
Why?
|
| Virus Replication | 1 | 2003 | 319 | 0.010 |
Why?
|
| Bone Screws | 1 | 2001 | 44 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2003 | 193 | 0.010 |
Why?
|
| Tics | 1 | 2001 | 4 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 1991 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2001 | 180 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 859 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2001 | 267 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1538 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2001 | 242 | 0.010 |
Why?
|
| Swine | 1 | 2001 | 555 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2001 | 425 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1981 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 1014 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 2001 | 241 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1999 | 274 | 0.010 |
Why?
|
| Dominance, Cerebral | 1 | 1998 | 66 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2001 | 449 | 0.010 |
Why?
|
| Decision Making | 1 | 2004 | 642 | 0.010 |
Why?
|
| Graft Survival | 1 | 2001 | 884 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1999 | 329 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1997 | 156 | 0.010 |
Why?
|
| Simplexvirus | 1 | 1997 | 151 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 1995 | 176 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1995 | 155 | 0.010 |
Why?
|
| Palliative Care | 1 | 1994 | 257 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1994 | 468 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1995 | 999 | 0.010 |
Why?
|
| Iothalamate Meglumine | 1 | 1991 | 5 | 0.010 |
Why?
|
| Autoradiography | 1 | 1991 | 69 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1991 | 156 | 0.010 |
Why?
|
| Equipment Design | 1 | 1991 | 406 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1991 | 269 | 0.010 |
Why?
|
| Yttrium | 1 | 1983 | 3 | 0.000 |
Why?
|
| Iridium | 1 | 1983 | 3 | 0.000 |
Why?
|
| Radioisotopes | 1 | 1983 | 45 | 0.000 |
Why?
|
| Radiation Injuries, Experimental | 1 | 1983 | 41 | 0.000 |
Why?
|
| Edema | 1 | 1983 | 71 | 0.000 |
Why?
|